Who Should Avoid Turmeric Supplements
This page is about supplements. With two partial exceptions noted where they arise, none of what follows is an argument against turmeric in cooking. For most groups on this list, the concerns in the research attach to the concentrated capsule, not to the spice in food.
The groups below are not equally strong. Some rest on human trials with a clear mechanism; some rest on a handful of case reports where the consequences of being wrong are severe enough to justify caution anyway; one rests mostly on the absence of study. Each section says which it is, because a caution means more when the reason behind it is known.
Table of Contents
- Spice Is Not Supplement
- Gallstones and Bile-Duct Obstruction
- Calcium-Oxalate Kidney Stones
- Iron Deficiency and Low Iron Stores
- Surgery, Dental Work and Bleeding Risk
- Transplant Recipients and Narrow-Therapeutic-Index Drugs
- Existing Liver Disease
- Pregnancy and Breastfeeding
- Children, Reflux and Sensitive Stomachs
- What the Trials Actually Dosed
- Why the Literature Itself Needs Care
- The Recap
- Key Research Papers
- Connections
- Featured Videos
Spice Is Not Supplement
Before the list, the distinction that makes sense of all of it.
Turmeric powder is mostly starch and fibre, with curcuminoids at a few percent, and those curcuminoids are absorbed so poorly that even a heavily spiced diet produces low blood concentrations. That is the exposure under which turmeric earned its long, quiet safety record across more than a thousand years of daily use.
A standardised extract concentrates curcuminoids to around 95% — a twenty- to thirtyfold step before anything else happens — and modern formulations then add a delivery system engineered specifically to defeat poor absorption. Black-pepper extract blocks the enzymes that dispose of curcumin; phospholipid complexes, submicron colloids, solid lipid particles and micelles each attack a different barrier. The result is intentional: several times more curcumin in the blood at the same label dose. Our bioavailability and forms page explains the engineering.
So for most of the groups below, the research concerns the concentrated supplement, not turmeric as a spice — the spice was never the thing at issue.
Gallstones and Bile-Duct Obstruction
Evidence: human ultrasound studies. This is one of the better-supported cautions here.
Rasyid and Lelo published a placebo-controlled ultrasound study in Alimentary Pharmacology & Therapeutics in 1999 examining the effect of curcumin on human gallbladder function. In a randomized, double-blind crossover study in 12 healthy volunteers, 20 mg of curcumin reduced gallbladder volume by 29.3% at 2 hours, a significant difference from placebo: curcumin caused the gallbladder to contract. Rasyid, Rahman, Jaalam and colleagues followed this in the Asia Pacific Journal of Clinical Nutrition in 2002 with a study of different curcumin doses on the human gallbladder. In 12 healthy volunteers, 20, 40 and 80 mg of curcumin reduced gallbladder volume by 34.10%, 51.15% and 72.25% at 2 hours, and 40 mg was the dose that produced a 50% contraction. All of these doses are tens of milligrams of curcumin.
The mechanism is straightforward and, in most circumstances, entirely benign. The gallbladder stores bile and squeezes it into the small intestine when fat arrives. Turmeric is a cholagogue — a substance that prompts that squeeze — which is one of the oldest documented traditional uses of the plant and part of why it appears in digestive formulas across several medical traditions. Healthy gallbladder, working duct: the squeeze is normal physiology and helps with fat digestion.
The problem is a gallbladder with a stone in the wrong place, or a duct that is blocked or narrowed. Now you have a muscular organ contracting hard against an obstruction, which is the anatomy of biliary colic — the severe, gripping right-upper-abdomen pain that sends people to emergency departments. Stimulating that contraction works against that anatomy.
Who this applies to: anyone with known gallstones, a history of biliary colic, a bile-duct obstruction or stricture, or a known biliary abnormality. If you have had your gallbladder removed, it does not apply — there is no gallbladder left to contract, and bile simply drains continuously.
This is one of the two entries where large culinary intakes are worth a thought, since the effect is a response to turmeric itself rather than to a formulation. Ordinary seasoning is not the concern; a daily golden-milk habit built on heaped spoonfuls, in somebody with symptomatic stones, is a larger exposure. Right-sided pain that reliably follows turmeric-heavy food is information about the gallbladder, not just about the dinner.
Calcium-Oxalate Kidney Stones
Evidence: a human crossover study with a clean comparator.
Tang, Larson-Meyer and Liebman published a study in the American Journal of Clinical Nutrition in 2008 on the effect of cinnamon and turmeric on urinary oxalate excretion, plasma lipids and plasma glucose in healthy subjects. Turmeric raised urinary oxalate excretion. Cinnamon did not.
The internal comparison is what makes this study worth citing. Two spices, the same design, the same participants, and only one produced the effect — which is far more informative than a single-arm observation, because it rules out a generic effect of "eating a spice" and points at turmeric's own oxalate content and how it is handled.
Why oxalate matters: the most common kidney stones are calcium oxalate. They form when calcium and oxalate concentrations in the urine are high enough for crystals to nucleate and grow. Dietary oxalate is one of several contributors — fluid intake, urine calcium, citrate, sodium and the balance of calcium in the same meal all matter too — but for people who form these stones repeatedly, oxalate intake is one of the levers doctors actually pull, which is why low-oxalate diets exist.
Who this applies to: people who have formed calcium-oxalate stones, and particularly anyone following a low-oxalate diet on medical advice. A high-dose turmeric supplement works against a low-oxalate diet: Tang and colleagues found that 91% of turmeric's oxalate was water-soluble, against 6% for cinnamon, which appeared to be the primary cause of the greater urinary oxalate excretion from turmeric. How much this matters depends on whether a person's stones are oxalate-driven at all, which urine chemistry shows.
This is the second entry where culinary amounts deserve a mention, because it is the spice's own oxalate that was measured. The usual stone-prevention measures are ordinary: more fluid, turmeric taken with a calcium-containing food (calcium binds oxalate in the gut, so less is absorbed), and a total kept in proportion. For people who have never had a kidney stone, this is not a reason to change anything.
Iron Deficiency and Low Iron Stores
Evidence: a well-characterised mechanism in animals and cells, plus one human case report.
Jiao, Wilkinson, Di and colleagues showed in Blood in 2009 that curcumin acts as a biologically active iron chelator — binding iron and producing the downstream signs of iron depletion in animals, not merely sticking to iron in a test tube. Smith and Ashar then reported in Cureus in 2019 a case of iron-deficiency anaemia attributed to high-dose turmeric, which resolved when the turmeric was stopped.
One case report is a weak foundation on its own. Paired with a demonstrated mechanism and a resolution on withdrawal, it is enough to be worth knowing about — particularly since the people most at risk are easy to identify in advance.
Who this applies to:
- Anyone diagnosed with iron-deficiency anaemia or low ferritin.
- People with heavy menstrual bleeding.
- Vegetarians and vegans, whose dietary iron is less readily absorbed to begin with.
- People with coeliac disease, inflammatory bowel disease or other malabsorption, and anyone who has had bariatric surgery.
- Blood donors who give regularly.
- Anyone taking an iron supplement, since the binding happens in the gut.
For people in these groups, a ferritin test (the blood test for iron stores) before starting and again after a few months shows whether iron stores are falling. That converts an invisible risk into a measured one, which is the general theme of this leg of the site.
For people with normal iron stores, mild chelation is not obviously a problem, and some of curcumin's proposed effects have been attributed to this very property. The concern is specific to those whose iron is already low.
Surgery, Dental Work and Bleeding Risk
Evidence: a theoretical mechanism. The one human interaction study found nothing. A pause before surgery is still common practice, for the reason below.
Curcumin has been shown in laboratory work to interfere with platelet aggregation. That is the basis for turmeric appearing on every "herbs that thin the blood" list, and it is a reasonable mechanistic concern.
It is also, so far, unconfirmed in people. Hu, Belcaro, Dugall and colleagues studied a bioavailable curcumin formulation alongside antiplatelet agents, anticoagulants and thyroid replacement therapy in 2018 and reported no significant interaction. That study has limits — observational, one formulation, and a null result can reflect limited power — but it is the human evidence available, and reporting it accurately matters more than preserving a tidy warning. Our drug-interactions page covers the anticoagulant question in full.
The reason a pause before surgery is still common practice is the shape of the decision, not the strength of the evidence. Pausing a supplement for one to two weeks costs essentially nothing — no supplement on earth delivers a benefit that collapses over a fortnight. Bleeding during or after an operation costs a great deal. When one side of a decision is free and the other is expensive, strong evidence is not needed to choose; the possibility of an effect is enough. That is prudence, and it is labelled here as prudence rather than dressed up as a proven danger.
The usual practice: turmeric supplements are commonly paused one to two weeks before planned surgery, dental extractions, colonoscopy with likely biopsy, injections into joints or the spine, and cosmetic procedures. Supplements are frequently omitted from medication lists, and anaesthetists and surgeons want to know about them. Food-level turmeric is not part of this pause. The supplement is usually restarted once the surgeon is satisfied with the wound.
Transplant Recipients and Narrow-Therapeutic-Index Drugs
Evidence: two human case reports of an interaction, and one monitored case test that found none. The firmest caution on this page, and not because the evidence is strongest.
A narrow-therapeutic-index drug is one where the gap between too little and too much is small. Tacrolimus and cyclosporine — the calcineurin inhibitors that stop a transplanted organ being rejected — are the classic examples, which is why recipients have blood levels measured repeatedly, sometimes for the rest of their lives. Too low risks the graft; too high damages the kidneys.
Three case reports involve turmeric. Two describe an interaction: Nayeri and colleagues described acute calcineurin-inhibitor nephrotoxicity following turmeric intake, and a 2010 Swedish report, published without a listed author, described a possible turmeric–tacrolimus interaction. The third found none. Boissiere and colleagues gave a kidney-transplant patient on tacrolimus 10 g/day of turmeric for 4 days, then 10 g/day of curry for 4 days, then 10 g/day of ginger for 4 days, with close monitoring of blood tacrolimus levels, and observed no change in tacrolimus plasma concentrations during or after the protocol; they wrote that the impact of these spices "seems negligible in vivo although further studies are needed". The plausible mechanism behind the two positive reports is interference with the enzymes and transporters that clear these drugs — the same route by which grapefruit juice raises tacrolimus, which transplant teams already warn about.
Two positive case reports would normally support a mild caution at most. The caution is firm here for the reason set out on the interactions page: the cost of skipping a turmeric supplement is zero, and the cost of being wrong is graft rejection or kidney injury. That asymmetry decides it.
Who this applies to: anyone with a transplanted organ; anyone on tacrolimus, cyclosporine or similar immunosuppression for any reason; and, by the same logic, people on other narrow-index medicines — lithium, digoxin, some antiepileptics, and drugs whose levels are routinely monitored. Curcumin has not been studied with most of those, which is exactly the point: an unstudied variable added to a finely titrated regimen is a bad trade.
For culinary amounts, the Boissiere test is the most direct evidence: 10 g a day of turmeric, curry or ginger did not change one patient's tacrolimus levels. It was a single patient, the authors note that further studies are needed, and they describe testing the effect of spice consumption, with level monitoring, as a shared decision that "seems reasonable" for a patient whose diet involves these spices. In most contexts "it's only food" is a fair argument. In transplant medicine it is weaker than usual.
Existing Liver Disease
Evidence: an inference from the case literature rather than a study of this group.
There is an irony here worth naming. Turmeric is widely promoted for liver health, and there is real research behind that interest — our page on turmeric and liver health covers it. Yet the best-documented harm from concentrated turmeric supplements is liver injury.
Both can be true, and the resolution is the same as everywhere else on this leg: the trials studying benefit and the case reports describing harm are describing different exposures, different products and different people. But it does mean that existing liver disease changes the picture, for three reasons:
- Less reserve. A liver already compromised by fatty liver disease, hepatitis, cirrhosis or an autoimmune condition has less capacity to absorb an additional insult.
- Harder to detect. If your liver enzymes are already abnormal, the rise that would signal drug-induced injury in someone else is much harder to spot against your background.
- Harder to attribute. If something goes wrong, working out whether it was the supplement or the underlying disease is genuinely difficult, and that uncertainty complicates your care.
The same applies if you drink heavily, take other medicines known to affect the liver, or have had drug-induced liver injury from anything before — a previous idiosyncratic reaction is a marker of susceptibility.
Halegoua-DeMarzio and Navarro's review in Liver International on the challenges of identifying and preventing herbal-induced liver injury is the honest overview of this field. It reports that liver injury from herbal and dietary supplements has increased significantly over the past three decades in the US Drug-Induced Liver Injury Network, which now attributes 20% of its cases of drug-induced liver injury to these products, and it names turmeric among the major implicated agents.
The same network's turmeric case series found 10 cases of turmeric-associated liver injury enrolled between 2004 and 2022, all since 2011. The injury was hepatocellular in 9 of the 10, typically appeared after 1 to 4 months, and 1 patient died of acute liver failure. Seven of the 10 patients carried the immune gene type HLA-B*35:01, an allele frequency of 0.450 against 0.056–0.069 in population controls. Three of the 7 products tested also contained piperine (black pepper), and the authors wrote that liver injury due to turmeric "appears to be increasing in the United States, perhaps reflecting usage patterns or increased combination with black pepper".
In 2026 the dietary-supplement expert committee of the United States Pharmacopeia reviewed the safety evidence. It found that "Numerous clinical trials involving turmeric- or curcuminoid-containing supplements have not reported organ toxicity or serious adverse events", while published case reports of liver injury "often involve concomitant medications or supplements". Reported liver injury typically occurs after 1 to 4 months of use and generally resolves when the product is stopped; cases of acute liver failure have been reported, albeit rarely. The committee recommended a cautionary statement for its turmeric and curcuminoid monographs: liver problems "have been reported very rarely" in people taking these supplements; people with a history of liver problems are told to consult a health-care practitioner before use; and the warning signs named are "abdominal pain, dark urine, or jaundice (yellowing of the skin or eyes)", on which the statement says to stop the product and seek medical advice. The full picture is on our liver-injury page.
Pregnancy and Breastfeeding
Evidence: an absence of study, which is not the same as evidence of harm. This section deliberately cites no paper, because none in our verified set addresses pregnancy.
Here is the honest position, in two parts.
Turmeric as a food is regarded as fine. It is eaten daily throughout pregnancy across enormous populations and has been for many centuries, and it is a normal part of the diet in cultures where it is a kitchen staple. Curry is not the concern.
Turmeric supplements at concentrated doses are not well studied in pregnancy. That is a statement about the state of the literature, not about danger. Pregnant women are, for understandable reasons, excluded from most trials of most substances, which means the evidence base for supplements in pregnancy is thin almost across the board. A reader deserves to be told that clearly rather than handed either a false reassurance or a false alarm.
What follows from a genuine unknown is a matter of judgement, and the judgement most people reach is the conservative one: during pregnancy and breastfeeding, they get turmeric from food, where the safety record is long and the dose is modest, and leave the concentrated extract until afterwards. Not because it has been shown to cause harm — it has not — but because the reason to take a supplement during pregnancy has to be strong enough to outweigh an unmeasured risk, and for most people it is not.
For a pregnant woman who has already been taking a turmeric supplement, this is not cause for alarm, because no harm has been shown. Where the supplement is taken for a specific medical condition, the same fact applies: concentrated doses have not been studied in pregnancy, so the trade-off is between that condition and an unmeasured risk.
To read the primary literature yourself: PubMed: Curcumin and pregnancy safety and PubMed: Turmeric during lactation and breastfeeding.
Children, Reflux and Sensitive Stomachs
Two smaller groups, handled briefly and honestly.
Children. Turmeric in food is normal for children in every cuisine that uses it. Concentrated supplements for children are a different question, and the evidence base is essentially the same as for pregnancy: thin, because children are rarely enrolled in supplement trials. Dosing has not been established, children are not small adults metabolically, and the case for giving a healthy child a concentrated botanical extract is usually weak. For a child with a condition for which someone has suggested curcumin, the facts are these: no dose has been established, and the trial evidence in children is thin. Relevant reading: PubMed: Curcumin supplementation in children.
Reflux and sensitive stomachs. Turmeric stimulates bile flow and gastric secretion, and a minority of people find that concentrated doses produce heartburn, reflux, nausea or loose stools. This is a tolerability issue rather than a safety one — unpleasant, not dangerous — and it is dose-related in a way that idiosyncratic liver injury is not. Taking it with food usually helps, as does a lower dose. A supplement that consistently makes the stomach worse is causing symptoms every day, which is a tolerability signal in itself. Our page on turmeric and digestive health covers the gut effects in both directions, since the same bile-stimulating property that bothers some people is the basis of its traditional digestive use.
What the Trials Actually Dosed
It helps to know what "high dose" means in the hands of people doing this deliberately, under supervision. Three phase I studies give the scale.
Cheng, Hsu, Lin and colleagues (2001), in Anticancer Research, ran a phase I trial of curcumin in 25 patients with high-risk or pre-malignant lesions, escalating oral doses to find the limits of tolerability: from 500 mg/day up through 1,000, 2,000, 4,000, 8,000 and 12,000 mg/day, each taken for 3 months. There was "no treatment-related toxicity up to 8,000 mg/day"; beyond 8,000 mg/day, "the bulky volume of the drug was unacceptable to the patients".
Sharma, McLelland, Hill and colleagues (2001), in Clinical Cancer Research, gave oral Curcuma extract to 15 patients with advanced colorectal cancer, at 440–2200 mg/day containing 36–180 mg of curcumin, for up to 4 months. It measured markers in the patients' blood cells and looked for curcumin in blood, urine and faeces — a study designed as much to understand the absorption problem as to test an effect. Neither curcumin nor its metabolites were detected in blood or urine, but curcumin was recovered from faeces.
Kanai, Otsuka, Otsuka and colleagues (2013), in Cancer Chemotherapy and Pharmacology, did the equivalent work with a highly bioavailable colloidal curcumin formulation in patients with pancreatic or biliary tract cancer, giving 200 mg or 400 mg of curcumin a day with gemcitabine-based chemotherapy. Median peak plasma curcumin levels were 324 ng/mL at 200 mg and 440 ng/mL at 400 mg — the modern version of the question, where the delivery problem has been partly solved.
Three things follow for a general reader. First, gram-level daily doses were tolerated by most participants in short, monitored courses, which is genuinely reassuring about acute toxicity. Second, the doses in the Cheng study ran into the grams because the body discards most of it — in the Sharma study, neither curcumin nor its metabolites were detected in blood or urine at up to 180 mg of curcumin a day. The size of the number reflects the absorption problem, not a therapeutic requirement. Third, and most important: these were supervised trials in patients with serious illness, with monitoring and follow-up. They are not a licence for anyone to take grams of curcumin daily, indefinitely, unsupervised, in a formulation designed to deliver several times more into the blood than the trials achieved. That combination — high dose, enhanced absorption, long duration, nobody watching — is the profile that shows up in the case literature.
Why the Literature Itself Needs Care
A page about who the research raises concerns for owes the reader one more thing: a reason to be sceptical of the enthusiasm on the other side.
Nelson, Dahlin, Bisson and colleagues (2017), in the Journal of Medicinal Chemistry: "The Essential Medicinal Chemistry of Curcumin." This is the most cited critique in the field. Its argument is that curcumin is what chemists call a PAINS compound — pan-assay interference — and an invalid metabolic panacea. Molecules of this type have chemical properties that make them produce apparent hits in a very wide range of laboratory assays through mechanisms unrelated to genuine biological activity: interfering with fluorescence readouts, reacting non-specifically with proteins, aggregating and dragging targets down with them. The paper also notes that despite decades of intense study, no curcumin formulation had succeeded in a definitive clinical trial in the way the laboratory literature would predict.
This is not a fringe position, and it does not say curcumin does nothing. It says the enormous in-vitro literature — the source of most "curcumin targets 200 molecular pathways" claims — is much less reliable than its volume suggests, and that claims should rest on human trials.
Burgos-Morón, Calderón-Montaño, Salvador and colleagues (2010), in the International Journal of Cancer: "The dark side of curcumin." A review collecting the evidence that curcumin is not uniformly benign — that at some concentrations and in some systems it produces effects nobody would want, which is a normal property of biologically active molecules and an abnormal thing to find discussed in supplement marketing.
Two further papers are worth naming for anyone comparing bioavailability claims, because they concern how the measurements are made. Stohs and colleagues (2019) argued that the enzymatic-hydrolysis method commonly used to determine curcumin in plasma is a flawed indicator of bioavailability, and Luis and colleagues (2020) showed that the hydrolysis step is incomplete, with complex conjugates detectable in plasma. Between them they imply that some published bioavailability multiples rest on an assay that may not measure what it claims — which is worth knowing when a label advertises a number.
The practical reading is equal scepticism of "curcumin cures everything" and "turmeric destroys your liver." Both claims are usually built out of laboratory findings promoted beyond their weight. The defensible middle is that concentrated curcumin is a real biologically active substance with modest evidence for some uses, an uncommon but genuine capacity for harm, and a product category where what is on the label and what reaches your blood are not the same number.
The Recap
The single most useful sentence on this page: spice is not supplement.
Turmeric in your cooking is one of the best-established safe foods there is. Eaten daily by hundreds of millions of people for centuries, it delivers a small amount of a poorly absorbed compound, and none of the harms documented in this leg of the site come from it. Nothing on this page is about removing turmeric from food.
A concentrated curcumin supplement, particularly an absorption-enhanced one, is a different proposition. It is a pharmacological dose of a biologically active molecule, and it calls for the same handling as any other: a reason for taking it, a defined dose, an end point, an eye on interactions, and attention to how you feel. That is not a warning about turmeric. It is what taking anything seriously looks like.
For most of the groups on this page, the research concerns the capsule, not turmeric in cooking — and for many of them the capsule was not going to deliver much anyway.
Key Research Papers
- Rasyid A, Lelo A. (1999). The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther. — PubMed PMID: 10102956
- Rasyid A, Rahman AR, Jaalam K, et al. (2002). Effect of different curcumin dosages on human gall bladder. Asia Pac J Clin Nutr. — PubMed PMID: 12495265
- Tang M, Larson-Meyer DE, Liebman M. (2008). Effect of cinnamon and turmeric on urinary oxalate excretion, plasma lipids, and plasma glucose in healthy subjects. Am J Clin Nutr. — PubMed PMID: 18469248
- Jiao Y, Wilkinson J 4th, Di X, et al. (2009). Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood. — PubMed PMID: 18815282
- Smith TJ, Ashar BH. (2019). Iron Deficiency Anemia Due to High-dose Turmeric. Cureus. — PubMed PMID: 30899609
- Hu S, Belcaro G, Dugall M, et al. (2018). Interaction study between antiplatelet agents, anticoagulants, thyroid replacement therapy and a bioavailable formulation of curcumin (Meriva). Eur Rev Med Pharmacol Sci. — PubMed PMID: 30070343
- Boissiere C, Francois E, Vabret E, et al. (2023). Spice-drug interactions: a case report on the use of turmeric, curry and ginger in a renal transplant patient on tacrolimus. Eur J Hosp Pharm. — PubMed PMID: 37586787
- Nayeri A, Wu S, Adams E, et al. (2017). Acute Calcineurin Inhibitor Nephrotoxicity Secondary to Turmeric Intake: A Case Report. Transplant Proc. — PubMed PMID: 28104136
- (2010). [Interaction between turmeric and tacrolimus possible]. Lakartidningen. — PubMed PMID: 20521597 (no author list is returned for this record)
- Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. (2023). Liver Injury Associated with Turmeric—A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]. Am J Med. — PubMed PMID: 36252717
- Halegoua-DeMarzio D, Navarro V. (2025). Challenges in herbal-induced liver injury identification and prevention. Liver Int. — PubMed PMID: 39136211
- Akhtar N, Barnes J, Gardiner P, et al. (2026). Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. Pharm Biol. — PubMed PMID: 42364655
- Cheng AL, Hsu CH, Lin JK, et al. (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. — PubMed PMID: 11712783
- Sharma RA, McLelland HR, Hill KA, et al. (2001). Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res. — PubMed PMID: 11448902
- Kanai M, Otsuka Y, Otsuka K, et al. (2013). A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol. — PubMed PMID: 23543271
- Nelson KM, Dahlin JL, Bisson J, et al. (2017). The Essential Medicinal Chemistry of Curcumin. J Med Chem. — PubMed PMID: 28074653
- Burgos-Morón E, Calderón-Montaño JM, Salvador J, et al. (2010). The dark side of curcumin. Int J Cancer. — PubMed PMID: 19830693
- Stohs SJ, Chen CYO, Preuss HG, et al. (2019). The fallacy of enzymatic hydrolysis for the determination of bioactive curcumin in plasma samples as an indication of bioavailability. BMC Complement Altern Med. — PubMed PMID: 31684927
- Luis PB, Kunihiro AG, Funk JL, et al. (2020). Incomplete Hydrolysis of Curcumin Conjugates by β-Glucuronidase: Detection of Complex Conjugates in Plasma. Mol Nutr Food Res. — PubMed PMID: 31962379
- Shoba G, Joy D, Joseph T, et al. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. — PubMed PMID: 9619120
PubMed Topic Searches
Connections
- Turmeric Safety and Drug Interactions
- Turmeric and Liver Injury
- Turmeric Drug Interactions
- Lead in Turmeric
- Bioavailability and Forms
- Turmeric for Liver Health
- Turmeric and Digestive Health
- Heart and Metabolic Health
- Anti-Inflammatory and Joint Health
- Turmeric Benefits
- Turmeric
- Culinary and Spice Herbs
- Gut Health
- Herbs